Sirtris Pharmaceuticals to Present at the Lazard Healthcare Conference November 29th 2006 and Piper Jaffray Healthcare Conference December 1st 2006

Cambridge, MA –November 28th, 2006 -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that it will be presenting at the Lazard Annual Healthcare Conference on November 29th at 1:30 pm EST and the Piper Jaffray Annual Healthcare Conference on December 1st at 10:10 am EST in New York. Sirtris will discuss the Company’s strategy for discovering and developing first in class therapeutics that modulate sirtuins, a recently discovered family of enzymes that promote healthy cellular function.

About Sirtuins

Sirtuins are a recently discovered family of enzymes that promote normal cellular function. In particular, sirtuins improve the function of mitochondria which generate energy in cells. When organisms face adversity, sirtuins are activated as part of a natural process that maintains healthy function.

Therefore, sirtuins are attractive drug targets which may be therapeutically beneficial for diseases in which mitochondria are dysfunctional, often observed in diseases of aging. These diseases include metabolic diseases such as Type 2 Diabetes and other mitochondrial disorders. Sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging in a new way.

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company developing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging in the areas of metabolic and mitochondrial diseases.

Sirtris Pharmaceuticals was founded in 2004 by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal and has raised a total of $82 million since inception from investors including: Bessemer Venture Partners, Cardinal Partners, Cargill Ventures, Genzyme Ventures, Novartis Bioventures Fund, Polaris Venture Partners, QVT Fund LP, Skyline Ventures, The Wellcome Trust, Three Arch Partners, and TVM Capital. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.